Morgan Stanley analyst Sean Laaman assumed coverage of Erasca (ERAS) with an Overweight rating and $4 price target The firm sees potential upside from naporafenib and readthroughs in the (K)RAS space, the analyst tells investors in a research note. Morgan Stanley also says it is encouraged by the preclinical profiles of ERAS-0015 and ERAS-4001, but notes that it will take time for clinical data to be generated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS: